47 results about "Aromatic hydrocarbon receptor" patented technology

The present invention relates to a method of screening compounds for binding to hsp90 by exposing a compound to hsp90 or a polypeptide fragment thereof containing amino acid residues 538-728 of the full length protein and determining whether the compound binds to hsp90 of the polypeptide fragment thereof. Also disclosed is a method of screening compounds for inhibition of hsp90 activity. The present invention further relates to a method of screening compounds as a cancer therapeutic and a method of treating cancerous conditions. Also disclosed is a method of inhibiting transcription-inducing activity of an aryl hydrocarbon receptor in a cell and a method of modifying expression of a gene that is activated by an aryl hydrocarbon receptor.

The invention discloses an aromatic hydrocarbon receptor modulator shown in a formula (I) and a pharmaceutically acceptable salt thereof. The formula (I) is described in the specification, wherein R'is H, CN, CH2(OH)RO, CmH2m+1, CnH2n-1, CnH2n-3 or two groups (described in the specification), and two Ra groups are independently H or jointly form =O or =N-W3-R1; A is a C6-C10 aromatic ring unsubstituted or with 1-3 R substituted, a C2-C10 heteroaromatic ring mixed with 1-5 heteroatoms selected from N, O and S or a quaternary to heptatomic nonaromatic heterocyclic ring which is mixed with 1-3 heteroatoms selected from N, O and S and contains C=N; Q is R, or a C6-C10 aromatic ring unsubstituted or with 1-3 R substituted, or a C2-C10 heteroaromatic ring mixed with 1-5 heteroatoms selected from N, O and S; and R is RC connected with C or RN connected with N. The compound shown in a formula (I) can regulate AhR activity and can be used for inhibiting cancer cell growth as well as migrationand invasion of tumor cells.

The purpose of the present invention is to provide a probiotic(s) which can activate an aromatic hydrocarbon receptor (AhR) and can consequently prevent inflammatory damage in the digestive tract. The present invention relates to; a probiotic(s) capable of activating an AhR; an anti-inflammatory agent comprising the probiotic(s); an orally ingestible composition containing the anti-inflammatory agent; and a method for screening for the probiotic(s).

Provided herein are methods of cancer treatment by administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its structural analogs to a patient with cancer, for example, prostate, liver, lung, ovarian, breast, skin, colon (or rectum), stomach, pancreatic, kidney, bladder, soft tissue, or cervical cancer.

Uses of ethyl 5,11-dihydroindolo[3,2-b]carbazole-6-carboxylate as a fluorescent ligand probe, preferably in a binding assay for quantitative analysis in combination with a recombinant aryl hydrocarbon receptor (AhR) protein. A method for detection or quantitative analysis of suspected aryl hydrocarbon receptor (AhR) ligands in a sample, the method comprising the steps of: (a) providing a sample possibly containing at least one known or unknown AhR ligand; (b) mixing said sample with a composition comprising a recombinant AhR protein bound to ethyl 5,11-dihydroindolo[3,2-b]carbazole-6-carboxylate; and (c) determining the presence or the total amount of said at least one known or unknown AhR ligand in the sample by fluorescence spectroscopy. Use e.g. for screening of unknown compounds to determine their binding ability to AhR; for analyzing unknown chemical mixtures to assess the presence of ligands able to bind to AhR; for screening of Polycyclic Aromatic Hydrocarbon (PAHs) from water, food or sediment; for screening of PAHs or dioxin-like compounds in water, food or sediment; for testing for pollutant removal in water and waste water treatment plants; for testing for water reuse; for testing the presence of dioxin-like compounds in incinerator plants; or for testing of bodily fluids of humans or animals exposed to PAHs or dioxin-like compounds.

The present invention provides a new application of aryl hydrocarbon receptor (AhR) in predicting the effect of immunotherapy, specifically, the present invention provides the application of AhR as a target in the development, screening and / or preparation of drugs for treating tumors , also provides the application of the reagents for inhibiting, silencing and / or knocking out AhR in the preparation of drugs for treating tumors, and also provides the use of reagents for detecting the level of AhR in the preparation for predicting the effect of immune checkpoint inhibitors in treating tumors application in agents.

The invention discloses a compound 5-(4-hydroxyl-3-methoxyl benzylidene)-2-(2-nitryl phenylimino) thiazolidone, HMNT for short, and an application thereof in an aromatic hydrocarbon receptor stimulant, wherein the chemical structure is as shown in a formula (I). Experiments verify that the compound disclosed by the invention effectively causes up-regulation of genetic expression and protein expression of a metabolic enzyme CYP1A1 of a related allogenic material of a downstream target gene of an aromatic hydrocarbon receptor in a mouse hepatoma carcinoma cell at the concentration of 10 mu M and prompts that the compound is the aromatic hydrocarbon receptor stimulant, is expected to become a potential drug by taking the aromatic hydrocarbon receptor as a tumor treating target, and is wide in clinical application prospect.